Physician profile
John Michael Cocco
NPI 1194941724
$2,568.97
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,453 · 2020: $125 · 2021: $211 · 2022: $556 · 2023: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $614.72 | 2019-2022 | |
| Amgen INC. | $316.78 | 2019-2023 | Evenity |
| Allergan, INC. | $260.10 | 2019-2020 | |
| Radius Health, INC. | $225.02 | 2019 | |
| Lilly USA, LLC | $187.82 | 2019 | |
| Novo Nordisk INC | $125.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $124.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.52 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $108.33 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.27 | 2022 | |
| Merck Sharp & Dohme LLC | $101.45 | 2019 | |
| Esperion Therapeutics, INC. | $100.19 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $90.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $84.61 | 2019 | |
| Glaxosmithkline, LLC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cocco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.